Photocure ASA (PHCUF) has released an update.
Photocure ASA, known as the Bladder Cancer Company, has partnered with Equity Pharmaceuticals to launch a Named Patient Program (NPP) in South Africa, allowing physicians to access Hexvix for bladder cancer patients without local licensing. The program, starting in Q4 2024, aims to improve diagnosis and management of bladder cancer where blue light cystoscopy (BLC) is available but Hexvix is not. This initiative reflects Photocure’s commitment to expanding global access to its diagnostic technology as a part of its sustainability goals.
For further insights into PHCUF stock, check out TipRanks’ Stock Analysis page.
